导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.57% | 2666/4773 |
| 近一周 | -2.09% | 1201/5462 |
| 近一月 | -4.00% | 2133/5421 |
| 近一季 | -6.94% | 2245/5209 |
| 近半年 | -2.50% | 1920/4920 |
| 近一年 | 1.15% | 2388/4366 |
| 近两年 | 45.48% | 1625/2954 |
| 近三年 | 27.83% | 1146/2253 |
| 成立以来 | 140.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.41% 3188/4961 |
11.57% 2319/5312 |
- - |
- - |
| 2025 | 19.75% 2187/4813 |
-0.93% 2473/3635 |
2.18% 1787/4076 |
17.76% 2443/4524 |
0.46% 1988/4813 |
| 2024 | 16.76% 767/3463 |
2.79% 700/2808 |
-1.12% 943/3014 |
16.59% 1409/3129 |
-1.48% 1718/3463 |
| 2023 | -9.20% 1126/2656 |
4.23% 1013/2280 |
-3.88% 949/2385 |
-2.88% 781/2515 |
-6.67% 1866/2655 |
| 2022 | -19.28% 830/2207 |
-13.68% 813/1919 |
6.48% 691/2016 |
-13.61% 930/2113 |
1.67% 1181/2208 |
| 2021 | -2.20% 840/1822 |
-2.34% 621/1255 |
4.08% 925/1330 |
-5.28% 789/1466 |
1.58% 868/1822 |
| 2020 | 27.45% 579/1250 |
-9.55% 687/1028 |
12.89% 662/1067 |
10.53% 538/1164 |
12.93% 413/1184 |
| 2019 | 34.57% 400/1092 |
25.95% 434/754 |
-0.59% 276/804 |
0.63% 497/850 |
6.80% 546/918 |
| 2018 | -23.27% 274/834 |
- - |
- - |
- - |
-11.65% 331/691 |
| 2017 | 20.91% 175/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.97% 234/605 |
- - |
- - |
- - |
- - |
| 2015 | 6.75% 186/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 国寿安保沪深300ETF联接A VS. 长安沪深300非周期A(740101) |